Tao Shandong, Wang Chunling, Chen Yue, Deng Yuan, Song Lixiao, Shi Yuyue, Ling Lanlan, Ding Banghe, He Zhengmei, Yu Liang
Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China.
Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Oncol Lett. 2019 Dec;18(6):6766-6774. doi: 10.3892/ol.2019.11051. Epub 2019 Nov 5.
The FMS-like tyrosine kinase 3-internal tandem duplication () gene mutation is present in ~20% of patients with acute myeloid leukemia (AML). Patients with an mutation have a poor prognosis. However, the prognostic function of combined with other cytogenetic abnormalities are not clear. In the present study, a retrospective analysis of 103 newly diagnosed patients with AML was performed. The results revealed that the overall survival (OS) and recurrence-free survival (RFS) times were significantly longer in patients with an mutation combined with other favorable risk genes, compared with in those patients with a single mutation (P=0.0361 and P=0.0426). Sorafenib combined with chemotherapy significantly improved the overall response rate (ORR) when compared with mono-chemotherapy (P=0.039), but no significant differences were observed in the OS and RFS. In conclusion, favorable-risk cytogenetics may improve the clinical outcomes of patients with -mutated AML, but adverse-risk cytogenetics may not further worsen the prognosis. Sorafenib combined with chemotherapy may increase the ORR but would not result in a longer OS and RFS.
约20%的急性髓系白血病（AML）患者存在FMS样酪氨酸激酶3内部串联重复（）基因突变。存在该突变的患者预后较差。然而，该突变与其他细胞遗传学异常相结合的预后功能尚不清楚。在本研究中，对103例新诊断的AML患者进行了回顾性分析。结果显示，与单一该突变患者相比，该突变与其他有利风险基因相结合的患者的总生存期（OS）和无复发生存期（RFS）显著更长（P = 0.0361和P = 0.0426）。与单一化疗相比，索拉非尼联合化疗显著提高了总缓解率（ORR）（P = 0.039），但在OS和RFS方面未观察到显著差异。总之，有利风险细胞遗传学可能改善该突变型AML患者的临床结局，但不利风险细胞遗传学可能不会进一步恶化预后。索拉非尼联合化疗可能会提高ORR，但不会导致更长的OS和RFS。
